Octreotide acetate
Bynfezia Pen, Mycapssa, Sandostatin, Sandostatin Lar (octreotide acetate) is a protein pharmaceutical. Octreotide acetate was first approved as Bynfezia pen on 1988-10-21. It is used to treat acromegaly, adenoma, diarrhea, pancreatic neoplasms, and pituitary neoplasms in the USA. Sandostatin's patents are valid until 2036-02-03 (FDA).
| Trade Name | Bynfezia Pen, Mycapssa, Sandostatin, Sandostatin Lar |
|---|---|
| Common Name | Octreotide acetate |
| Indication | acromegaly, adenoma, diarrhea, pancreatic neoplasms, pituitary neoplasms |
| Drug Class | Peptides: inhibition of growth hormone release |
